The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation

• Main Authors: Dina Baier (Author), Beatrix Schoenhacker-Alte (Author), Mate Rusz (Author), Christine Pirker (Author), Thomas Mohr (Author), Theresa Mendrina (Author), Dominik Kirchhofer (Author), Samuel M. Meier-Menches (Author), Katharina Hohenwallner (Author), Martin Schaier (Author), Evelyn Rampler (Author), Gunda Koellensperger (Author), Petra Heffeter (Author), Bernhard Keppler (Author), Walter Berger (Author)
• Format: Book
• Published: MDPI AG, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Cellular energy metabolism is reprogrammed in cancer to fuel proliferation. In oncological therapy, treatment resistance remains an obstacle and is frequently linked to metabolic perturbations. Identifying metabolic changes as vulnerabilities opens up novel approaches for the prevention or targeting...